CN116801882A - 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 - Google Patents

杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 Download PDF

Info

Publication number
CN116801882A
CN116801882A CN202280011390.5A CN202280011390A CN116801882A CN 116801882 A CN116801882 A CN 116801882A CN 202280011390 A CN202280011390 A CN 202280011390A CN 116801882 A CN116801882 A CN 116801882A
Authority
CN
China
Prior art keywords
compound
group
ret
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280011390.5A
Other languages
English (en)
Chinese (zh)
Inventor
陈忠辉
袁晓曦
雷冬梅
韩润丰
韩晓军
田强
宋宏梅
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN116801882A publication Critical patent/CN116801882A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280011390.5A 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 Pending CN116801882A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110316525 2021-03-24
CN2021103165256 2021-03-24
CN2022074619 2022-01-28
CN2022101097668 2022-01-28
CNPCT/CN2022/074619 2022-01-28
CN202210109766 2022-01-28
PCT/CN2022/081890 WO2022199503A1 (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Publications (1)

Publication Number Publication Date
CN116801882A true CN116801882A (zh) 2023-09-22

Family

ID=83396096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280011390.5A Pending CN116801882A (zh) 2021-03-24 2022-03-21 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Country Status (7)

Country Link
US (1) US20250268897A1 (cg-RX-API-DMAC7.html)
EP (1) EP4316490A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511389A (cg-RX-API-DMAC7.html)
KR (1) KR20230159367A (cg-RX-API-DMAC7.html)
CN (1) CN116801882A (cg-RX-API-DMAC7.html)
AU (1) AU2022242476A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022199503A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7688690B2 (ja) * 2020-07-28 2025-06-04 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
CN120897743A (zh) 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) * 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022732A1 (en) * 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2019143977A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2020114474A1 (zh) * 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
WO2020168939A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2020235945A1 (ko) * 2019-05-21 2020-11-26 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2021023209A1 (zh) * 2019-08-05 2021-02-11 北京志健金瑞生物医药科技有限公司 含氮多环稠环类化合物,其药物组合物、制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180022732A1 (en) * 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2019143977A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2020114474A1 (zh) * 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
WO2020168939A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2020235945A1 (ko) * 2019-05-21 2020-11-26 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2021023209A1 (zh) * 2019-08-05 2021-02-11 北京志健金瑞生物医药科技有限公司 含氮多环稠环类化合物,其药物组合物、制备方法和用途

Also Published As

Publication number Publication date
EP4316490A1 (en) 2024-02-07
EP4316490A4 (en) 2025-03-05
AU2022242476A1 (en) 2023-10-26
WO2022199503A1 (zh) 2022-09-29
JP2024511389A (ja) 2024-03-13
KR20230159367A (ko) 2023-11-21
US20250268897A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
WO2021043077A1 (zh) 一种取代吡嗪化合物、其制备方法和用途
JP6200520B2 (ja) 置換2−アミノピリジンプロテインキナーゼ阻害剤
CN118055933B (zh) 选择性parp1抑制剂及其应用
CN113316578B (zh) 杂环化合物、包含其的药物组合物及其制备方法和用途
EP4316490A1 (en) Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor
US20160280719A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN112574201B (zh) 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN120897743A (zh) 杂环化合物治疗与ret基因改变相关疾病的用途和方法
CN119301101A (zh) 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
CA3130478A1 (en) Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient
CN118434736A (zh) 含有肼基的化合物
RU2828045C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение
CA3210109A1 (en) Use of heterocyclic compound in treating diseases related to kinase drug-resistant mutation and method therefor
CN116761801A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
EP4556478A1 (en) Tgf-beta inhibitor compound and use thereof
CN117126140A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CA3300307A1 (en) Jak inhibitor compound and use thereof
CN116903626A (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
AU2024323272A1 (en) Jak inhibitor compound and use thereof
HK40051009A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
HK1207862B (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination